RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma. PURPOSE: This research study is looking at T cells in blood and bone marrow samples from patients with multiple myeloma.
OBJECTIVES: Primary * To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs) in peripheral blood and bone marrow samples from patients with multiple myeloma. Secondary * To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo using interferon γ release and CD3/CD28 stimulation. OUTLINE: Peripheral blood and bone marrow samples are collected periodically for laboratory studies. Samples are analyzed to assess the feasibility of expanding autologous B cells ex vivo using CD40L and IL-4; the antigen-presenting phenotype of autologous B-cell antigen-presenting cells (B-APCs) using flow cytometry; and the antigen-presenting function of B-APCs using ELISPOT and chromium-release assay. Myeloma-specific interferon γ secreting T cells are isolated and selected using Miltenyi beads. The selected myeloma-specific T cells are expanded ex vivo using anti CD3/CD28 beads.
Study Type
OBSERVATIONAL
Enrollment
6
Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry
Time frame: Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
Cell Counts of Myeloma-specific T Cells ex Vivo Expanded Before and After CD3/CD28 Stimulation
Time frame: Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.